Drug Profile
Research programme: respiratory syncytial virus vaccines - AmVac
Alternative Names: AMV-601; AMV-602; AMV-603; AMV-611; RespiVacLatest Information Update: 03 Mar 2023
Price :
$50
*
At a glance
- Originator AmVac
- Developer AmVac; University of Siena
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Parainfluenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Parainfluenza virus infections (Prevention) in Switzerland (Intranasal) (AmVac pipeline, February 2023)
- 23 Feb 2023 Discontinued - Preclinical for Respiratory syncytial virus infections (Prevention) in Italy (Intranasal) (AmVac pipeline, February 2023)
- 23 Feb 2023 Discontinued - Preclinical for Respiratory syncytial virus infections (Prevention) in Switzerland (Intranasal) (AmVac pipeline, February 2023)